Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia.
作者信息
Perica Karlo, Flynn Jessica, Curran Kevin J, Rivere Isabelle, Wang Xiuyan, Senechal Brigitte, Halton Elizabeth, Diamonte Claudia, Pineda John, Bernal Yvette, Gonen Mithat, Sadelain Michel, Brentjens Renier J, Park Jae H
机构信息
Department of Medicine, Cellular Therapy Center, New York, NY, USA.
Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
Leukemia. 2021 Nov;35(11):3268-3271. doi: 10.1038/s41375-021-01196-3. Epub 2021 Mar 8.
Abstract
摘要
相似文献
1
Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia.桥接化疗对成人急性淋巴细胞白血病中CD19嵌合抗原受体T细胞疗法临床结局的影响
Leukemia. 2021 Nov;35(11):3268-3271. doi: 10.1038/s41375-021-01196-3. Epub 2021 Mar 8.
2
Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia.用于复发/难治性小儿急性淋巴细胞白血病的人源化靶向CD19嵌合抗原受体T（CAR-T）细胞
Am J Hematol. 2021 May 1;96(5):E162-E165. doi: 10.1002/ajh.26123. Epub 2021 Feb 21.
3
Using CD19 chimeric antigen receptor-T cell therapy in a 4-month-old patient with infantile acute lymphoblastic leukemia.在一名4个月大的婴儿急性淋巴细胞白血病患者中使用CD19嵌合抗原受体T细胞疗法。
Pediatr Blood Cancer. 2020 Apr;67(4):e28155. doi: 10.1002/pbc.28155. Epub 2020 Jan 11.
4
Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.利用靶向CD19的嵌合抗原受体T细胞对慢性淋巴细胞白血病和费城染色体阳性急性淋巴细胞白血病进行联合治疗。
Leuk Lymphoma. 2018 Jul;59(7):1717-1721. doi: 10.1080/10428194.2017.1390237. Epub 2017 Oct 18.
5
Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.儿童和青年复发性/难治性急性淋巴细胞白血病中 CD19 特异性嵌合抗原受体 T 细胞治疗的系统评价和荟萃分析：安全性和疗效结局。
Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e334-e347. doi: 10.1016/j.clml.2020.12.010. Epub 2020 Dec 17.
6
Therapy Options in Treating Acute Lymphoblastic Leukemia in Adults.成人急性淋巴细胞白血病的治疗选择
Oncology (Williston Park). 2019 Jul 16;33(7):629385.
7
Shortening the ex vivo culture of CD19-specific CAR T-cells retains potent efficacy against acute lymphoblastic leukemia without CAR T-cell-related encephalopathy syndrome or severe cytokine release syndrome.缩短CD19特异性嵌合抗原受体（CAR）T细胞的体外培养时间，在不发生CAR T细胞相关脑病综合征或严重细胞因子释放综合征的情况下，仍保留对急性淋巴细胞白血病的强大疗效。
Am J Hematol. 2019 Dec;94(12):E322-E325. doi: 10.1002/ajh.25630. Epub 2019 Oct 2.
8
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.新型抗 CD19 嵌合抗原受体构建的 CD19 CAR T 在复发或难治性急性淋巴细胞白血病中的疗效和安全性。
J Hematol Oncol. 2020 Sep 7;13(1):122. doi: 10.1186/s13045-020-00953-8.
9
Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies.CD19 CAR T 细胞疗法治疗急性淋巴细胞白血病后复发的机制及其预防和治疗策略。
Front Immunol. 2019 Nov 12;10:2664. doi: 10.3389/fimmu.2019.02664. eCollection 2019.
10
CAR T-cell therapy effective in B acute lymphoblastic leukaemia.嵌合抗原受体T细胞疗法对B细胞急性淋巴细胞白血病有效。
Lancet Oncol. 2017 Jun;18(6):e314. doi: 10.1016/S1470-2045(17)30364-9. Epub 2017 May 18.
引用本文的文献
1
The Changing Role of Allogeneic Stem Cell Transplantation in Adult B-ALL in the Era of CAR T Cell Therapy.在CAR-T细胞疗法时代，异基因干细胞移植在成人B细胞急性淋巴细胞白血病中的角色转变
Curr Oncol. 2025 Mar 19;32(3):177. doi: 10.3390/curroncol32030177.
2
Mitigation and Management of Common Toxicities Associated with the Administration of CAR-T Therapies in Oncology Patients.肿瘤患者接受CAR-T疗法相关常见毒性的缓解与管理
Drug Saf. 2025 Mar 19. doi: 10.1007/s40264-025-01538-5.
3
Adoptive Cell Therapy from the Dish: Potentiating Induced Pluripotent Stem Cells.源自培养皿的过继性细胞疗法：增强诱导多能干细胞
Transfus Med Hemother. 2024 Aug 26;52(1):27-41. doi: 10.1159/000540473. eCollection 2025 Feb.
4
Venetoclax in combination with chidamide and azacitidine for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia with the gene: a case report and literature review.维奈托克联合西达本胺和阿扎胞苷治疗伴有该基因的复发/难治性B细胞急性淋巴细胞白血病：1例病例报告及文献复习
Front Immunol. 2025 Jan 14;15:1475974. doi: 10.3389/fimmu.2024.1475974. eCollection 2024.
5
Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy.嵌合抗原受体T细胞在结直肠癌中的应用：开创实体瘤免疫治疗的新途径
J Clin Oncol. 2025 Mar 10;43(8):994-1005. doi: 10.1200/JCO-24-02081. Epub 2025 Jan 13.
6
Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma.桥接治疗后代谢肿瘤体积的反应决定了大 B 细胞淋巴瘤嵌合抗原受体 T 细胞治疗的结果。
Clin Cancer Res. 2024 Nov 15;30(22):5083-5093. doi: 10.1158/1078-0432.CCR-24-0830.
7
Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukemia in children and young adults.儿童和青年复发/难治性B系急性淋巴细胞白血病患者在嵌合抗原受体T细胞治疗前的桥接治疗方法。
Haematologica. 2024 Dec 1;109(12):3892-3903. doi: 10.3324/haematol.2023.283780.
8
Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies.自体 CAR T 细胞制造失败和/或血液系统恶性肿瘤疗效的早期预测因素。
Blood Adv. 2024 Jan 23;8(2):337-342. doi: 10.1182/bloodadvances.2023011992.
9
CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.用于治疗B细胞急性淋巴细胞白血病的嵌合抗原受体T细胞
J Clin Med. 2023 Oct 31;12(21):6883. doi: 10.3390/jcm12216883.
10
The Interplay between T Cells and Cancer: The Basis of Immunotherapy.T 细胞与癌症的相互作用：免疫疗法的基础。
Genes (Basel). 2023 Apr 28;14(5):1008. doi: 10.3390/genes14051008.
Zotero 插件